Caris Life Sciences (CAI) Stock Price, News & Analysis

Company Overview

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis. In addition to clinical testing for patient care, the company offers translational science and clinical trial support services to biopharmaceutical partners, including biomarker discovery, assay development and companion diagnostic collaborations to facilitate drug development programs.

The company primarily serves healthcare providers, cancer centers and biopharma customers in the United States and through international collaborations. Its offerings are used across the oncology care continuum—from initial profiling to inform therapy selection through longitudinal monitoring and research applications—positioning the business at the intersection of clinical diagnostics and precision oncology research.

Caris emphasizes the integration of multi‑omic data and computational analysis to generate clinically actionable insights, and it engages with clinicians, researchers and industry partners to expand the use of molecular profiling in personalized cancer care. Detailed information about its leadership and corporate history is available through the company’s public filings and corporate disclosures.

Key Stats

• Today's Range: $20.78 to $21.64
• 50-Day Range: $15.38 to $23.40
• 52-Week Range: $14.19 to $42.50
• Volume: 3.59 million shs
• Average Volume: 4.81 million shs
• Market Capitalization: $5.93 billion
• P/E Ratio: 58.25
• Dividend Yield: N/A
• Price Target: $26.33
• Consensus Rating: Moderate Buy

Caris Life Sciences Stock Analysis - MarketRank™

Caris Life Sciences scored higher than 74% of companies evaluated by MarketBeat, and ranked 156th out of 909 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Caris Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 7 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Caris Life Sciences has a consensus price target of $26.33, representing about 25.6% upside from its current price of $20.97.

Amount of Analyst Coverage

Caris Life Sciences has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 223.08%

Earnings Growth

Earnings for Caris Life Sciences are expected to grow by 223.08% in the coming year, from $0.13 to $0.42 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Caris Life Sciences is 58.25, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 45.30.

Price to Earnings Ratio vs. Sector

The P/E ratio of Caris Life Sciences is 58.25, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 270.31.

Price to Book Value per Share Ratio

Caris Life Sciences has a P/B Ratio of 10.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.44% of the float of Caris Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Caris Life Sciences has a short interest ratio ("days to cover") of 4.21.

Change versus previous month

Short interest in Caris Life Sciences has recently increased by 25.76%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Caris Life Sciences does not currently pay a dividend.

Dividend Growth

Caris Life Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.90

News Sentiment

Caris Life Sciences has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Caris Life Sciences this week, compared to 4 articles on an average week.

Search Interest

6 people have searched for CAI on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Caris Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

50.00% of the stock of Caris Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Caris Life Sciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 2/26/2026
• Today: 8/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:CAI
• CIK: 2019410
• Web: www.carislifesciences.com
• Phone: (866) 771-8946
• Fax: N/A
• Employees: 1,846
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Caris Life Sciences: $26.33
• High Price Target: $33.00
• Low Price Target: $21.00
• Potential Upside/Downside: +25.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.36
• Trailing P/E Ratio: 58.25
• Forward P/E Ratio: 161.31
• P/E Growth: N/A
• Net Income: -$68.09 million
• Net Margins: 10.62%
• Pretax Margin: 10.61%
• Return on Equity: 18.77%
• Return on Assets: 9.34%

Debt

• Debt-to-Equity Ratio: 0.66
• Current Ratio: 5.53
• Quick Ratio: 4.88

Sales & Book Value

• Annual Sales: $812.03 million
• Price / Sales: 7.30
• Cash Flow: $1.53 per share
• Price / Cash Flow: 13.67
• Book Value: $2.05 per share
• Price / Book: 10.23

Miscellaneous

• Outstanding Shares: 282,600,000
• Free Float: 141,298,000
• Market Cap: $5.93 billion
• Optionable: N/A
• Beta: 0.68